144 related articles for article (PubMed ID: 11905734)
1. Programming of radiotherapy in the treatment of non-small-cell lung cancer--a way to advance care.
Saunders MI
Lancet Oncol; 2001 Jul; 2(7):401-8. PubMed ID: 11905734
[TBL] [Abstract][Full Text] [Related]
2. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee.
Saunders M; Dische S; Barrett A; Harvey A; Griffiths G; Palmar M
Radiother Oncol; 1999 Aug; 52(2):137-48. PubMed ID: 10577699
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).
Tsuchiya S; Ohe Y; Sugiura T; Fuwa N; Kitamoto Y; Mori K; Kobayashi H; Nakata K; Sawa T; Hirai K; Etoh T; Saka H; Saito A; Fukuda H; Ishizuka N; Saijo N;
Jpn J Clin Oncol; 2001 Oct; 31(10):488-94. PubMed ID: 11696618
[TBL] [Abstract][Full Text] [Related]
4. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee.
Saunders M; Dische S; Barrett A; Harvey A; Gibson D; Parmar M
Lancet; 1997 Jul; 350(9072):161-5. PubMed ID: 9250182
[TBL] [Abstract][Full Text] [Related]
5. High-dose hyperfractionated accelerated radiotherapy in non-small cell lung cancer.
De Ruysscher D; Reymen B; Van Baardwijk A
Minerva Chir; 2011 Aug; 66(4):341-5. PubMed ID: 21873969
[TBL] [Abstract][Full Text] [Related]
6. Accelerated hyperfractionated radiotherapy combined with induction and concomitant chemotherapy for inoperable non-small-cell lung cancer--impact of total treatment time.
Nyman J; Bergman B; Mercke C
Acta Oncol; 1998; 37(6):539-45. PubMed ID: 9860311
[TBL] [Abstract][Full Text] [Related]
7. Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer.
Saunders MI; Rojas A; Lyn BE; Pigott K; Powell M; Goodchild K; Hoskin PJ; Phillips H; Verma N
Br J Cancer; 1998 Nov; 78(10):1323-8. PubMed ID: 9823973
[TBL] [Abstract][Full Text] [Related]
8. From CHART to CHARTWEL in non-small cell lung cancer: clinical radiobiological modelling of the expected change in outcome.
Bentzen SM; Saunders MI; Dische S
Clin Oncol (R Coll Radiol); 2002 Oct; 14(5):372-81. PubMed ID: 12555876
[TBL] [Abstract][Full Text] [Related]
9. Dose and fractionation concepts in the primary radiotherapy of non-small cell lung cancer.
Baumann M; Appold S; Petersen C; Zips D; Herrmann T
Lung Cancer; 2001 Sep; 33 Suppl 1():S35-45. PubMed ID: 11576706
[TBL] [Abstract][Full Text] [Related]
10. Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer.
Saunders MI; Rojas A; Lyn BE; Wilson E; Phillips H
Clin Oncol (R Coll Radiol); 2002 Oct; 14(5):352-60. PubMed ID: 12555873
[TBL] [Abstract][Full Text] [Related]
11. Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Eastern Cooperative Oncology Group.
Auchter RM; Scholtens D; Adak S; Wagner H; Cella DF; Mehta MP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1199-206. PubMed ID: 11483329
[TBL] [Abstract][Full Text] [Related]
12. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial.
Ball D; Bishop J; Smith J; O'Brien P; Davis S; Ryan G; Olver I; Toner G; Walker Q; Joseph D
Radiother Oncol; 1999 Aug; 52(2):129-36. PubMed ID: 10577698
[TBL] [Abstract][Full Text] [Related]
13. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
[TBL] [Abstract][Full Text] [Related]
14. HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer.
De Ruysscher D; Wanders R; van Haren E; Hochstenbag M; Geraedts W; Pitz C; Simons J; Boersma L; Verschueren T; Minken A; Bentzen SM; Lambin P
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):132-8. PubMed ID: 18037581
[TBL] [Abstract][Full Text] [Related]
15. Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer.
Uitterhoeve AL; Belderbos JS; Koolen MG; van der Vaart PJ; Rodrigus PT; Benraadt J; Koning CC; González González D; Bartelink H
Eur J Cancer; 2000 Mar; 36(5):592-600. PubMed ID: 10738123
[TBL] [Abstract][Full Text] [Related]
16. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: a retrospective review.
Nguyen LN; Komaki R; Allen P; Schea RA; Milas L
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1053-6. PubMed ID: 10421538
[TBL] [Abstract][Full Text] [Related]
18. Accelerated radical radiotherapy for non-small cell lung cancer using two common regimens: a single-centre retrospective study of outcome.
Pemberton LS; Din OS; Fisher PM; Hatton MQ
Clin Oncol (R Coll Radiol); 2009 Apr; 21(3):161-7. PubMed ID: 19111452
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
Socinski MA; Marks LB; Garst J; Sibley GS; Blackstock W; Turrisi A; Herndon J; Zhou S; Anscher M; Crawford J; Shafman T; Rosenman J
Oncologist; 2001; 6 Suppl 1():20-4. PubMed ID: 11182001
[TBL] [Abstract][Full Text] [Related]
20. Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial.
van Baardwijk A; Bosmans G; Bentzen SM; Boersma L; Dekker A; Wanders R; Wouters BG; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1103-10. PubMed ID: 18258382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
